company background image
KYMR logo

Kymera Therapeutics NasdaqGM:KYMR Stock Report

Last Price

US$47.67

Market Cap

US$3.1b

7D

-2.2%

1Y

312.7%

Updated

30 Oct, 2024

Data

Company Financials +

Kymera Therapeutics, Inc.

NasdaqGM:KYMR Stock Report

Market Cap: US$3.1b

KYMR Stock Overview

A biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural protein degradation system.

KYMR fundamental analysis
Snowflake Score
Valuation0/6
Future Growth2/6
Past Performance0/6
Financial Health6/6
Dividends0/6

Kymera Therapeutics, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Kymera Therapeutics
Historical stock prices
Current Share PriceUS$47.67
52 Week HighUS$53.27
52 Week LowUS$9.60
Beta2.22
11 Month Change0.72%
3 Month Change7.15%
1 Year Change312.73%
33 Year Change-26.81%
5 Year Changen/a
Change since IPO43.33%

Recent News & Updates

Kymera's Protein Degradation Technology: A Promising Bet For Long-Term Biotech Investors

Oct 06

Recent updates

Kymera's Protein Degradation Technology: A Promising Bet For Long-Term Biotech Investors

Oct 06

Analysts Are Upgrading Kymera Therapeutics, Inc. (NASDAQ:KYMR) After Its Latest Results

Aug 11
Analysts Are Upgrading Kymera Therapeutics, Inc. (NASDAQ:KYMR) After Its Latest Results

Kymera Therapeutics, Inc.'s (NASDAQ:KYMR) 27% Share Price Surge Not Quite Adding Up

Jul 14
Kymera Therapeutics, Inc.'s (NASDAQ:KYMR) 27% Share Price Surge Not Quite Adding Up

Shareholders Will Probably Hold Off On Increasing Kymera Therapeutics, Inc.'s (NASDAQ:KYMR) CEO Compensation For The Time Being

Jun 12
Shareholders Will Probably Hold Off On Increasing Kymera Therapeutics, Inc.'s (NASDAQ:KYMR) CEO Compensation For The Time Being

We Think Kymera Therapeutics (NASDAQ:KYMR) Can Easily Afford To Drive Business Growth

May 03
We Think Kymera Therapeutics (NASDAQ:KYMR) Can Easily Afford To Drive Business Growth

Kymera Therapeutics: Advancing Into Phase 2 With Partner Sanofi - I Still Have Faith

Mar 21

Kymera Therapeutics, Inc. (NASDAQ:KYMR) Released Earnings Last Week And Analysts Lifted Their Price Target To US$47.43

Feb 25
Kymera Therapeutics, Inc. (NASDAQ:KYMR) Released Earnings Last Week And Analysts Lifted Their Price Target To US$47.43

Optimistic Investors Push Kymera Therapeutics, Inc. (NASDAQ:KYMR) Shares Up 39% But Growth Is Lacking

Feb 17
Optimistic Investors Push Kymera Therapeutics, Inc. (NASDAQ:KYMR) Shares Up 39% But Growth Is Lacking

Kymera Therapeutics, Inc.'s (NASDAQ:KYMR) Shares Climb 33% But Its Business Is Yet to Catch Up

Dec 29
Kymera Therapeutics, Inc.'s (NASDAQ:KYMR) Shares Climb 33% But Its Business Is Yet to Catch Up

We Think Kymera Therapeutics (NASDAQ:KYMR) Needs To Drive Business Growth Carefully

Nov 06
We Think Kymera Therapeutics (NASDAQ:KYMR) Needs To Drive Business Growth Carefully

Industry Analysts Just Made A Substantial Upgrade To Their Kymera Therapeutics, Inc. (NASDAQ:KYMR) Revenue Forecasts

Aug 31
Industry Analysts Just Made A Substantial Upgrade To Their Kymera Therapeutics, Inc. (NASDAQ:KYMR) Revenue Forecasts

Here's Why We're Not Too Worried About Kymera Therapeutics' (NASDAQ:KYMR) Cash Burn Situation

Aug 04
Here's Why We're Not Too Worried About Kymera Therapeutics' (NASDAQ:KYMR) Cash Burn Situation

Kymera Therapeutics, Inc.'s (NASDAQ:KYMR) Share Price Not Quite Adding Up

May 21
Kymera Therapeutics, Inc.'s (NASDAQ:KYMR) Share Price Not Quite Adding Up

We're Hopeful That Kymera Therapeutics (NASDAQ:KYMR) Will Use Its Cash Wisely

Apr 16
We're Hopeful That Kymera Therapeutics (NASDAQ:KYMR) Will Use Its Cash Wisely

Companies Like Kymera Therapeutics (NASDAQ:KYMR) Are In A Position To Invest In Growth

Dec 28
Companies Like Kymera Therapeutics (NASDAQ:KYMR) Are In A Position To Invest In Growth

Kymera KT-333 gets FDA orphan drug status for blood cancer subtype

Sep 15

Shareholder Returns

KYMRUS BiotechsUS Market
7D-2.2%-0.2%-0.09%
1Y312.7%27.0%38.6%

Return vs Industry: KYMR exceeded the US Biotechs industry which returned 27% over the past year.

Return vs Market: KYMR exceeded the US Market which returned 38.6% over the past year.

Price Volatility

Is KYMR's price volatile compared to industry and market?
KYMR volatility
KYMR Average Weekly Movement7.5%
Biotechs Industry Average Movement9.7%
Market Average Movement6.1%
10% most volatile stocks in US Market15.2%
10% least volatile stocks in US Market3.0%

Stable Share Price: KYMR has not had significant price volatility in the past 3 months compared to the US market.

Volatility Over Time: KYMR's weekly volatility (7%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2015181Nello Mainolfiwww.kymeratx.com

Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company develops STAT6, a Type 2 inflammation in allergic diseases; and TYK2, a treatment for inflammatory bowel disease, psoriasis, psoriatic arthritis, and lupus.

Kymera Therapeutics, Inc. Fundamentals Summary

How do Kymera Therapeutics's earnings and revenue compare to its market cap?
KYMR fundamental statistics
Market capUS$3.09b
Earnings (TTM)-US$157.85m
Revenue (TTM)US$88.55m

34.3x

P/S Ratio

-19.3x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
KYMR income statement (TTM)
RevenueUS$88.55m
Cost of RevenueUS$209.11m
Gross Profit-US$120.56m
Other ExpensesUS$37.30m
Earnings-US$157.85m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

Oct 31, 2024

Earnings per share (EPS)-2.48
Gross Margin-136.15%
Net Profit Margin-178.27%
Debt/Equity Ratio0%

How did KYMR perform over the long term?

See historical performance and comparison